# Immune imbalance and autoimmune mechanisms in plasma cell mastitis: current perspectives

## TL;DR

This review explores immune imbalances and autoimmune mechanisms in plasma cell mastitis, a non-bacterial breast disorder, to better understand its causes and improve treatment.

## Contribution

The paper provides a comprehensive overview of immune cell roles and imbalances in PCM, highlighting potential therapeutic targets.

## Key findings

- Immune cell imbalances, such as M1/M2 macrophages and Th17/Treg cells, are linked to PCM progression.
- The complement system and immune homeostasis regulation are potential areas for future research.
- Immune cell circadian rhythms and key immune pathways may offer new therapeutic strategies.

## Abstract

Plasma cell mastitis (PCM), also termed ductal dilatation or periductal mastitis (PDM), is a benign, non-bacterial inflammatory breast disorder predominantly affecting non-lactating women. Its incidence continues to rise, yet diagnosis and therapeutic approaches remain under development. Consequently, elucidating the pathogenesis is essential for identifying the disease’s root cause and facilitating breakthroughs. PCM is increasingly regarded as an autoimmune disorder, highlighting the crucial role of immune factors in its development; however, the precise immune mechanisms involved remain incompletely understood. Against these backgrounds, this review aims to: (1) discuss the contributions of various innate and adaptive immune cells within the PCM-associated immune microenvironment; (2) describe the relationship between imbalances in key immune cells (including M1/M2 macrophages, Th1/Th2 lymphocytes, Th17/Treg cells) and the progression of PCM; (3) explore potential future research areas, the underlying immunopathogenesis of PCM, and prospective therapeutic targets, the activation of the complement system, regulation of immune homeostasis, the role of immune cell circadian rhythms, and modulation of key immune pathways.